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 3 
Summary  36 
Background Lower respiratory tract infections (LRTIs) are a leading cause of childhood morbidity and 37 
mortality. Potentially pathogenic organisms are seen in both symptomatic and asymptomatic children 38 
and their presence does not per se indicate disease.  39 
Methods To assess the concordance between upper and lower respiratory tract microbiota during LRTI, 40 
we first studied 29 children with a severe LRTI and obtained paired nasopharyngeal swabs and deep 41 
endotracheal aspirates (PICU cohort). In addition, we performed a case-control study on 154 children 42 
hospitalized with a LRTI, and 307 age-, gender-, and time-matched healthy children to study the use of 43 
nasopharyngeal microbiota in discriminating LRTI from health. Nasopharyngeal samples of cases were 44 
obtained at time of hospital admission and of controls during home visits. Child characteristics were 45 
obtained by questionnaires, pharmacy printouts and medical charts. We used qPCR and 16S rRNA-46 
based sequencing to determine viral and bacterial microbiota profiles, respectively. 47 
Findings In the PICU cohort, there was a high intra-individual concordance of viral (96% agreement; 48 
95% CI 93-99%) and bacterial (Pearson’s r=0·93; IQR 0·62-0·99, p<0·05) microbiota profiles between 49 
nasopharyngeal and endotracheal aspirate samples, supporting the use of nasopharyngeal samples as 50 
proxy for lung microbiota during LRTI. In our matched case-control cohort we found that either bacterial 51 
microbiota, viruses or child characteristics performed poorly in distinguishing health from disease 52 
(random forest classification, AUC 0·77, 0·70, and 0·80, respectively). However, a classification model 53 
based on combined bacterial and viral microbiota, plus child characteristics distinguished children with 54 
LRTI with high accuracy from their matched controls (AUC 0·92).  55 
Interpretation Our data suggest that (i) nasopharyngeal microbiota may serve as a valid proxy for lower 56 
respiratory tract microbiota in childhood LRTI; (ii) clinical LRTI in children results from the interplay 57 
between microbiota and host characteristics, rather than a single microorganism; (iii) microbiota-based 58 
diagnostics may improve future diagnostic and treatment protocols. 59 
Funding Spaarne Gasthuis, University Medical Center Utrecht, and The Netherlands Organization for 60 
Scientific Research (NWO-Vidi grant 91715359).  61 
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 4 
Research in context 62 
Evidence before this study 63 
Conventional culture-based studies have identified key pathogens for the development of lower 64 
respiratory tract infection (LRTI). While the overgrowth of these potential pathogens might partly 65 
explain the progression towards disease, pathogen colonization (the act of settlement and reproduction 66 
of pathogens) per se does not necessarily lead to infection (the acquisition of a microorganism that leads 67 
to damage to the host). We hypothesized that the entire nasopharyngeal microbial community might 68 
play a role in the susceptibility to and severity of LRTIs. We searched PubMed on May 1st, 2018, using 69 
the terms “(Child, Preschool[mh] OR Infant[mh] NOT Infant, Newborn[mh]) AND (Respiratory Tract 70 
Infections[mh] OR pneumonia[tiab] OR bronchiolitis[tiab] OR wheezing[tiab]) AND (microbiota[mh] 71 
OR microbiome[tiab]) AND (Case-Control Studies[mh] OR prospective[tiab])”, with no language 72 
restrictions. We identified fourteen publications of which three reported on the role of the microbiota in 73 
acute LRTIs in children. One study demonstrated that specific microbiota profiles were associated with 74 
the development of respiratory infections in time and focused only on infants at high risk of atopy. A 75 
second study reported findings of a small (n=100) matched case-control study, but lacked matching on 76 
season, recruited a wide variety of children up to the age of 16 and more than half of their samples 77 
lacked sufficient bacterial DNA for further analysis. Therefore, it was underpowered to provide 78 
conclusive results. The third study included infants <1 year only and did not include a control group of 79 
healthy children. They showed that Moraxella was associated with less severe bronchiolitis and 80 
Streptococcus was associated with more severe bronchiolitis. Overall, the current evidence on the 81 
potential role of the microbial community in the pathogenesis and severity of LRTIs in children is 82 
limited.  83 
Added value of this study 84 
In our study, we used culture-independent techniques based on qPCR and 16S rRNA MiSeq sequencing 85 
of respiratory tract samples to ascertain first that the nasopharyngeal (viral and bacterial) microbiota can 86 
be used as proxy for lung microbiota in childhood LRTI, which is an important finding for future 87 
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 5 
diagnostic approaches. Next, we demonstrate the relation between microbial community composition 88 
and susceptibility to and severity of LRTIs in children. Since we used a strictly matched case-control 89 
design in a well-powered cohort of 461 children, our study is the first to confidently demonstrate the 90 
association between microbiota, including viral presence, and LRTI in children. To our knowledge, the 91 
accuracy of our model in discriminating LRTI from health is unprecedented. Also, the phenotype-92 
independent nature of the associations between respiratory microbiota and childhood LRTI has never 93 
been reported. 94 
Implications of all the available evidence 95 
Findings from this study broaden our knowledge on the likely important role of the complete 96 
nasopharyngeal ecosystem in the development and severity of LRTIs in young children. The excellent 97 
accuracy of our classifier model provides a premise for future microbiota-based diagnostic tools. Our 98 
data provide insights that may be critical for determining optimal therapeutic strategies, including 99 
targeted antibiotic treatment. The phenotype-independent associations during acute disease challenge 100 
conventional views on the role of viruses and bacteria in LRTI pathogenesis, especially the current 101 
dichotomy between bronchiolitis (viral origin) and pneumonia (bacterial origin). Our findings endorse 102 
studies to further explore microbiota-based diagnostics as a potential tool for clinical application in 103 
childhood LRTIs. This in turn may have major implications for the future treatment protocols.  104 




Lower respiratory tract infections (LRTIs) remain a major cause of morbidity and mortality in children 106 
worldwide.1,2 While multiple host, environmental, and lifestyle factors have been recognized to increase 107 
susceptibility to LRTIs,3 it remains unclear why some children remain asymptomatic upon pathogen 108 
exposure, while others develop severe disease. 109 
Classically, a LRTI is caused by acquisition of potentially pathogenic viruses and bacteria (pathobionts) 110 
in the upper respiratory tract, that replicate and spread towards the lower respiratory tract where they 111 
invade the mucosa leading to inflammation and clinical disease.4 Many pathobionts, however, are 112 
frequently encountered in the upper respiratory tract of healthy children.5 We hypothesize that that a 113 
balanced microbial community protects against development of LRTI.5  114 
Previous studies in children already demonstrated a relation between the bacterial microbiota 115 
composition of the nasopharynx and susceptibility to upper or lower respiratory infectious episodes over 116 
time.6,7 We recently described that oral microbes like Prevotella and Leptotrichia spp. in the 117 
nasopharyngeal niche were strongly associated with subsequent development of upper respiratory tract 118 
infections (URTIs) in children and are more abundant at times of an URTI. In contrast, Corynebacterium 119 
and Dolosigranulum spp. were associated with resistance to symptomatic respiratory disease over time 120 
and less present during URTI episodes.8 Additionally, in infants with respiratory syncytial virus (RSV) 121 
related LRTI, a strong correlation was observed between the presence of Haemophilus influenzae and 122 
Streptococcus pneumoniae and the severity of host inflammation, suggesting an important role for the 123 
complete microbial community in the upper respiratory tract and the symptomatology of clinical 124 
disease.9 125 
No study has yet addressed the relationship between the nasopharyngeal microbiota community and the 126 
presence, clinical symptoms and severity of childhood LRTI in a proper case-controlled manner. 127 
Moreover, nasopharyngeal microbiota profiling was never studied in the context of classification of 128 
states of health and disease. We, therefore, conducted a prospective strictly matched case-control study 129 
in young children hospitalized for a LRTI. We set out to demonstrate (i) the association between upper 130 
and lower respiratory tract microbiota during childhood LRTI; (ii) the use of microbiota to predict LRTI 131 
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presence and severity; and (iii) associations between microbiota and disease across different clinical 132 
presentations of LRTI, i.e. pneumonia, bronchiolitis and wheezing illness.  133 
Methods 134 
Details on the methods can be found in the appendix. Data have been deposited in the NCBI Sequence 135 
Read Archive database (BioProject ID PRJNA428382). This study conforms to the STROBE guide- 136 
lines for reporting case-control studies (Supplementary Table 3).10 137 
Study design and procedures 138 
We first conducted a prospective study from September 2013 to June 2015 enrolling 29 patients aged 4 139 
weeks to 5 years who became hospitalized at the pediatric intensive care unit of a university hospital 140 
(Wilhelmina Children's Hospital, Utrecht) for a WHO-defined LRTI11 requiring mechanical ventilation 141 
(PICU cohort; Supplementary Figure 1; patient characteristics: Supplementary Table 1). 142 
Nasopharyngeal swabs and endotracheal aspirates were obtained within four hours after intubation by 143 
trained nurses.  144 
Next to the PICU cohort, we conducted a prospective, matched case-control study from September 2013 145 
to June 2015, recruiting 154 cases under the same inclusion and exclusion criteria as the PICU cohort. 146 
Cases were recruited from three Dutch teaching hospitals (Spaarne Hospital, Hoofddorp; Kennemer 147 
Gasthuis, Haarlem; and St. Antonius Hospital, Nieuwegein). For each case, two age, gender, and time-148 
matched healthy controls from the community were recruited, with the exception of one case for whom 149 
only one matched healthy control could be recruited from the database (Supplementary Figure 1; 150 
baseline characteristics in Table 1). Nasopharyngeal swabs were taken of cases generally within 1 hour 151 
after admission, and of controls during a home visit. 152 
Of all children, extensive data regarding medical history and data on demographic, lifestyle and 153 
environmental characteristics were obtained. Both studies were approved by the Dutch National Ethics 154 
Committee. Written informed parental consent was obtained from all participants. 155 
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Two expert pediatricians independently classified all cases of the case-control cohort in three major 156 
disease phenotypes, i.e. pneumonia, bronchiolitis, and wheezing illness. Cases with a mixed or unclear 157 
phenotype were deemed ‘mixed’ phenotype. The expert panelists classified based on the entire medical 158 
record, including all clinical notes at and during admission, laboratory assessments and imaging. 159 
Microbiota analysis 160 
Bacterial DNA was isolated from samples as previously described.12 Amplification of the V4 161 
hypervariable region of the 16S rRNA gene was performed using barcoded universal primer pair 162 
533F/806R. Amplicon pools were sequenced using the Illumina MiSeq platform (San Diego, CA, USA) 163 
and processed in our bioinformatics pipeline as previously described.8 To avoid OTUs with identical 164 
annotations, we refer to OTUs using their taxonomical annotations combined with a rank number based 165 
on the abundance of each given OTU. In addition, viral profiles were determined using qualitative 166 
multiplex realtime-PCR (RespiFinder® SMARTfast 22) and identification of Streptococcus 167 
pneumoniae, Staphylococcus aureus, Haemophilus influenzae, and Moraxella catarrhalis was done by 168 
qPCR.  169 
Statistical analysis 170 
Data analysis was performed in R v3·2. All analyses assessing matched samples accounted for the 171 
matched nature of the samples. A p-value of less than 0·05 or a Benjamini-Hochberg (BH) adjusted q-172 
value of less than 0·05 was considered statistically significant. Statistical significance of the differences 173 
in baseline characteristics and viral detection was calculated with conditional logistic regression. 174 
Nonmetric multidimensional scaling (NMDS) plots were based on Bray-Curtis dissimilarity matrices 175 
and statistical significance was calculated by adonis (vegan). Host characteristics associated with 176 
microbiota composition were evaluated with a stepwise selected distance-based redundancy analysis,13 177 
and projected in NMDS plots using envfit (vegan). Hierarchical clustering was performed as described 178 
previously.9 Random forest analyses were used to determine biomarker species that most discriminate 179 
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 9 
between clusters (VSURF).14 We used metagenomeSeq and cross-validated VSURF analysis to identify 180 
specific microbial taxa associated with cases or controls.15 Sparse random forest classifier analyses were 181 
performed on the bacterial data, viral data, metadata, and the combination of all three datasets. 182 
Performance of these classifiers was evaluated by calculating the area under the receiver operating 183 
characteristic (ROC) curve (AUC) using the out-of-bag predictions for classification (pROC) as 184 
previously described.16 Since the potential real-world application of these classification models requires 185 
a more robust determination of biomarker bacteria, we also build the classification models using merged 186 
OTU on genus-level data. A cross-validated sparse random forest prediction model was built to 187 
investigate to what extend hospitalization duration could be predicted with all available data (caret). 188 
Above analyses were carried out for the entire case-control cohort and were in part repeated for each of 189 
the phenotypes independently. Additionally, in a post-hoc fashion, as a measure of disease severity, we 190 
stratified the cases according to the physicians’ judgment whether antibiotics were needed during 191 
admission (Dutch pediatricians generally restrict antibiotic treatment to children with clinically more 192 
severe LRTI) and performed separate analyses accordingly. 193 
Role of the funding source 194 
The funding sources had no role in the design, execution, analyses, or interpretation of the data of this 195 
study. The corresponding author had full access to the data final responsibility for the decision to submit 196 
for publication. 197 
Results 198 
Nasopharyngeal microbiota profiles correlate with lower respiratory tract microbiota during 199 
childhood LRTI 200 
To assess whether during acute LRTI in childhood the nasopharynx microbiota serves as a valid proxy 201 
for the lower respiratory tract microbiota, we first analyzed our PICU cohort. Viral presence in paired 202 
nasopharyngeal and endotracheal aspirates, were in almost full agreement (96%; 95% CI 93-99%). 203 
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Bacterial microbiota of paired samples showed good concordance in composition (median within Bray-204 
Curtis similarity 0·61) versus low concordance for between individual findings (median inter-individual 205 
BC similarity 0·10, p<0·001; Supplementary Figure 2A). Moreover, we observed a significantly 206 
correlated Shannon diversity (Pearson’s r 0·66, p<0·001). In addition, we observed that 58 taxa 207 
(combined relative abundance of 80·1%) were strongly correlated in the paired samples (median 208 
Pearson’s r=0·93, IQR 0·62-0·99, p<0·05); only three common members of nasopharyngeal microbiota 209 
Staphylococcus, Corynebacterium and Dolosigranulum were almost exclusively present in 210 
nasopharyngeal samples while absent in endotracheal aspirates (Pearson’s r<0·20, p>0·50; 211 
Supplementary Figure 2B). Vice versa, we could identify no taxa from the endotracheal samples that 212 
were not present in the nasopharynx. When assessing whether there were differences in the relative 213 
abundance for individual taxa between nasopharyngeal samples and endotracheal aspirates, we only 214 
found a significant result for Corynebacterium propinquum (Kruskal-Wallis test, Benjamini-Hochberg 215 
adjusted q=0·004), Corynebacterium macginleyi/accolens (q=0·019), Dolosigranulum pigrum 216 
(q=0·003), and three very low abundant taxa (median relative abundance <0·1%). The concordance did 217 
not depend on antibiotic treatment before sampling (n=5/29, 27%), the clinical suspicion of a bacterial 218 
infection (n= 20/29, 69%) or) or culture-confirmed bacterial infection (n=16/29, 55%).  219 
Host, lifestyle and environmental factors are associated with risk of disease  220 
In our separate, prospectively enrolled, matched case-control cohort, 40% were female and the median 221 
age was 13·6 months (IQR, 4·9 - 27·4). Cases had a history of more parental-reported RTIs, more 222 
wheezing symptoms, more recent antibiotic use, and more tobacco smoke exposure as compared to 223 
controls. Controls were breastfed for at least 3 months more often than cases, and the education level of 224 
parents of controls was higher than that of cases (all p<0·05, Table 1). 225 
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Host characteristics associated with microbial ecology in the healthy controls  226 
In our control cohort, respiratory microbiota composition was significantly associated with month of 227 
sampling (adonis, R2=6·2%) and age (R2=4·2%), followed by day-care attendance, breastfeeding, a 228 
history of parental-reported RTIs, and previous antibiotic treatment within the last 6 months (all p<0·05; 229 
Supplementary Figure 3). Gender was not correlated with microbiota composition.  230 
Viral and bacterial profile differences between cases and controls 231 
We detected one or multiple viruses in 97·1% of cases and 82·5% of controls (p<0·001; Figure 1), with 232 
a mean of 1·6 and 1·4 viruses/sample in cases and controls, respectively (p=0·04). The most commonly 233 
detected viruses were rhinovirus (62%), coronaviruses (18%), respiratory syncytial virus (17%), and 234 
adenoviruses (17%). Influenza was relatively rare (8%). In LRTI cases, we observed 10 times more 235 
often RSV (49% vs. 4·0%, p<0·001), and more human metapneumovirus (hMPV; 6·1% vs. 1·7%, 236 
p=0·022). Rhinovirus was more often detected in controls (67·3% vs 49·7%, p<0·001).  237 
With respect to bacterial microbiota, although cases did not have a higher bacterial biomass than controls 238 
(p=0·28), we observed a significant difference in overall microbiota composition between cases and 239 
controls (adonis, R2=3·1%, p<0·001; Figure 2A). Projection of the vectors for host characteristics 240 
associated with microbiota composition showed that previous antibiotic use in the past six months, 241 
recent bronchodilator use, and a parental-reported history of RTIs pointed in the direction of disease 242 
(envfit; Figure 2B). 243 
We observed seven distinct microbiota profiles within the cases and controls (hierarchical clustering; 244 
Supplementary Figure 4A). The profiles dominated by Haemophilus influenzae/haemolyticus (30·0% 245 
of samples) and Streptococcus pneumoniae (6·1%) were significantly related with LRTI cases, whereas 246 
profiles dominated by Moraxella catarrhalis/nonliquefaciens (47·3%), and Corynebacterium 247 
propinquum/Dolosigranulum pigrum (9·3%) were significantly associated with health (chi-square tests, 248 
p<0·05; Supplementary Figure 4B). A posteriori plotting of the biomarker species of these clusters in 249 
the NMDS ordination further supported the above associations between profiles and health or disease 250 
(Figure 2A). The profile dominated by H. influenzae/haemolyticus (median 126 pg/ul, Supplementary 251 
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Figure 4C) had a significant higher bacterial load than the other profiles (Wilcoxon rank-sum test, 252 
p<0·05), and a trend towards higher loads compared to S. aureus/epidermidis dominated profile (median 253 
82 pg/ul, p= 0·25). The bacterial load of the Streptococcus pneumoniae dominated profile (median 67 254 
pg/ul) was significantly higher than that of the C. propinquum & D. pigrum dominated profile (median 255 
15 pg/ul, p=0·002) though did not differ from that of the M. catarrhalis/nonliquefaciens dominated 256 
profile (median 35 pg/ul, p=0·40). 257 
On individual bacterial taxon level, we observed 49 taxa that differentiated cases from controls 258 
(metagenomeSeq, mean combined relative abundance 83·5%), which was confirmed for 17 of these 259 
bacteria by cross-validated random forest analysis (Supplementary Figure 5A). Among these, we 260 
observed a higher abundance of H. influenzae/haemolyticus, S. pneumoniae, Actinomyces spp., and 261 
Prevotella spp. in LRTI cases, while we observed a higher abundance of different Moraxella spp., C. 262 
propinquum, D. pigrum, and Helcococcus in controls.  263 
Clinical presentation independent viral and bacterial differences between cases and controls  264 
The classification of clinical phenotypes by an expert panel resulted in 37 cases of pneumonia, 57 cases 265 
of bronchiolitis, and 34 cases of wheezing illness. The remaining 26 cases were regarded as mixed 266 
phenotype (patient characteristics stratified per phenotype: Supplementary Table 2). RSV presence 267 
was predominant among all LRTI cases irrespective of phenotype, i.e. in 62% of bronchiolitis cases 268 
versus 3·6% in their matched controls (p<0·001), in 56% of pneumonia cases versus 4·1% in controls 269 
(p<0·001), in 58% of mixed-phenotype cases versus 1·9% in controls (p<0·001), and in 15% of 270 
wheezing illness cases versus 6·1% in controls (p=0·15; Supplementary Figure 6A). Rhinovirus was 271 
equally or less frequently detected in cases relative to controls. hMPV was only found in pneumonia 272 
and bronchiolitis cases. 273 
When we stratified per clinical phenotype, we again showed that the overall bacterial microbiota 274 
composition was significantly different between cases and controls for each phenotype (adonis, all 275 
p<0·01; Supplementary Figure 7). The differential abundance of individual microbes between cases 276 
and controls was highly similar for each phenotype (Supplementary Figure 5C-E). In all phenotypes 277 
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there was overrepresentation of Haemophilus, Neisseria and oral taxa, such as Actinomyces, and 278 
underrepresentation of multiple Moraxella, Dolosigranulum, and Helcococcus spp. The phenotype-279 
independent differences in microbiota composition between cases and controls were further 280 
strengthened by the results of the mixed-phenotype group, which largely overlapped that of the three 281 
other phenotypes (Supplementary Figure 5F).  282 
Combined importance for disease 283 
Combining viral and bacterial biomarkers with host factors in a sparse random forest analysis resulted 284 
in a very high classification accuracy of LRTI versus health (AUC 0·92; Figure 3A). The most 285 
important set of predictors of disease were the presence of RSV, a high abundance of H. 286 
influenzae/haemolyticus and S. pneumoniae, and low abundance of several Moraxella spp., together 287 
with recent antibiotic treatment, lack of breastfeeding and history of RTIs (Figure 3B). The combined 288 
classifier outperformed the models built on bacterial microbiota alone (AUC 0·77), viruses alone (AUC 289 
0·70), child characteristics alone (AUC 0·80) or the model including only the two classically most 290 
important pathobionts, i.e. RSV and S. pneumoniae (AUC 0·75). External validation of our classifier 291 
model on the samples of the PICU cohort, demonstrated a correct classification in 92% when testing on 292 
nasopharyngeal samples, and a correct classification in 100% when testing on endotracheal aspirates.  293 
Separate models for each of the phenotypes showed equally high accuracy in classifying LRTI (AUC 294 
0·90-0·94; Figure 3A, C-F). 295 
To test more broad and universally applicable classification models using bacterial microbiota data 296 
clustered on genus-level instead of OTU-level, we demonstrated again a very high classification 297 
accuracy of the presence of LRTI versus health (entire cohort AUC 0·92; phenotype-specific AUC 0·86-298 
0·94; Supplementary Figure 8). 299 
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Microbiota and severity of disease 300 
In post-hoc analyses we attempted to see whether a similar classification model could also predict 301 
severity of disease, which was a performed as stratified analyses within the LRTI group only. As a first 302 
measure, we studied whether or not the physician decided to start antibiotic treatment, after sampling of 303 
the nasopharynx, which occurred in 43/154 cases (28%); most for pneumonia cases (29/37, 78%) and 304 
few for bronchiolitis (4/57, 7%), wheezing illness (4/37, 12%), and mixed infection cases (6/26, 23%). 305 
Upon admission, the to-be-treated cases showed no differences in viral presence compared to the not-306 
to-be-treated cases (Supplementary Figure 6B). With respect to bacterial ecology, we observed similar 307 
though slightly more pronounced differences in microbiota compositions when compared to the matched 308 
controls in the to-be-treated cases compared to the not-to-be-treated cases (adonis, R2=5·8% and 309 
R2=2·6%, respectively, both p<0·001; Supplementary Figure 9). Antibiotic treatment prescription 310 
(following sampling), however, was not associated with increased abundance of pathobionts such as H. 311 
influenzae/haemolyticus or S. pneumoniae. Instead, there was a higher abundance of oral taxa, such as 312 
Veillonella, Prevotella, and Actinomyces spp. in the to-be-treated cases compared to the not-to-be-313 
treated cases (Supplementary Figure 5G-H).  314 
As a second measure of severity, we studied hospitalization duration, as a second measure of disease 315 
severity: this could be predicted fairly accurately at admission by a random forest model including 14 316 
viral, bacterial and host characteristics (Pearson’s r 0·50, p<0·001; Supplementary Figure 10). 317 
Predictors from highest to lowest importance were younger age, abundance of C. propinquum, 318 
Neisseria, S. aureus/epidermidis, S. thermophilus, Veillonella, P. melaninogenica, and other 319 
Streptococci, followed by disease phenotype, abundance of Atopobium, Lactobacillales, presence of 320 
RSV, absence of HRV, and abundance of Leptotrichia (Supplementary Figure 10A). When stratifying 321 
these data only for the not-to-be-treated group, the prediction of hospitalization duration at admission 322 
became stronger (Pearson’s r 0·55, p<0·001; Supplementary Figure 10C). For the to-be-treated group 323 
separately, the predictive capacity of the model was lost (p=0·73) suggesting interference of antibiotics 324 
with natural recovery.  325 
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As a third measure of severity, we analyzed the nasopharyngeal data of our PICU cohort in relation to 326 
matched with an age and season-matched subset of our case-control cohort. As expected, the overall 327 
microbiota compositions of the PICU cases demonstrated a similar but more pronounced shift from 328 
healthy controls compared to that of the (moderate-severe) cases from the case-control cohort (adonis, 329 
R2=5·6% and R2=4·2% for PICU versus case-control cohort, respectively; both p<0·001; 330 
Supplementary Figure 11A). Moreover, the PICU cases demonstrated an even more pronounced 331 
overrepresentation of several Haemophilus, Streptococcus (including S. pneumoniae), Veillonella and 332 
Actinomyces spp., and a more pronounced underrepresentation of multiple Moraxella, and especially 333 
Dolosigranulum and Corynebacterium spp. when compared to healthy controls (Supplementary 334 
Figure 5B and Supplementary Figure 11B).  335 
Discussion 336 
The upper respiratory tract microbiome is generally regarded the source community for the lower 337 
respiratory tract during LRTI in childhood,5 although this has rarely been proven, certainly not in young 338 
children with LRTI. Here, we show that in line with literature there is a high intra-individual 339 
concordance of viral17,18 and bacterial19,20 microbiota profiles between nasopharyngeal and endotracheal 340 
aspirate samples in LRTI cases admitted to a PICU. The Bray-Curtis similarity of 0·61 approximates 341 
that of biological replicates of microbiota profiles of the lungs (i.e. two sequentially obtained lavages 342 
from the same lung lobe of the same child).20 This suggests that the upper respiratory microbiota is not 343 
only the source community of the lower respiratory tract, but also that, except for a few commensal 344 
species, microbial colonization and proliferation in the nasopharynx parallels that of the lower airways 345 
during childhood LRTI. Therefore, our findings support the idea that upper respiratory tract samples can 346 
be used as proxy for lung microbiota in childhood LRTI.  347 
Next, in our unselected, strictly matched case-control cohort, we demonstrate a strong association 348 
between nasopharyngeal microbiota composition and the presence of childhood LRTIs. Viral presence 349 
was ubiquitous in both cases and controls, with in particular RSV and to a lesser extent hMPV highly 350 
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overrepresented in cases, in line with studies evaluating the viral etiology of childhood LRTIs.21 The 351 
presence and abundance of Haemophilus spp., S. pneumoniae and oral species were strongly associated 352 
with disease, in line with previous reports linking these taxa to susceptibility to and severity of RTIs in 353 
children.6,7,22,23 In contrast, the abundance of potentially beneficial bacteria like Moraxella, 354 
Corynebacterium, Dolosigranulum, and Helcococcus spp. were underrepresented in cases, in line with 355 
previous reports connecting these genera with prevention of infections.6,7,12,24 By combining viral, 356 
bacterial and host related predictors, we found that children with LRTIs can be uniquely differentiated 357 
from strictly matched healthy controls, while far less by the individual predictors. This underlines the 358 
multifactorial pathophysiology of childhood LRTI. The contribution of the nasopharyngeal microbiota, 359 
both bacterial and viral, appears largely independent of the clinical presentation, and even holds for 360 
bronchiolitis and wheezing illness that are generally assumed to be of viral etiology.  361 
Our results in the case-control study were confirmed independently in a second (PICU) cohort, 362 
especially showing nearly absent Corynebacterium and Dolosigranulum, suggesting that these children 363 
especially, had reduced resistance against overgrowth and dissemination of pathobionts to the lungs 364 
resulting in subsequent symptoms of LRTI.5 Also, the fact that in our post-hoc analyses the same oral 365 
species were associated with both the decision to treat with antibiotics and with hospitalization duration, 366 
suggests a causal role for these bacteria in the severity of LRTIs.25 A possible mechanism is that gram-367 
negative oral bacteria promote a pro-inflammatory mucosal response,26 leading to an increase in 368 
catecholamines that in turn accelerate the growth of these same gram-negative oral species, as well as 369 
that of potential pathogens such as Haemophilus spp. and S. pneumoniae.27,28 Therefore, hypothetically 370 
it seems interesting to study whether determining the abundance of oral bacteria in respiratory specimens 371 
and letting that result drive the decision to treat with antibiotics, would improve our outcome.  372 
So, what could be the implications of our finding? First, the unprecedented accuracy of our model in 373 
discriminating LRTI from health, makes microbiota-based diagnostics including viruses and bacteria, 374 
interesting as a potential tool for clinical application. Current diagnostics for detecting potentially 375 
pathogenic viruses and bacteria cover only a limited range of pathobionts and discriminate poorly 376 
between asymptomatic colonization or the cause of symptomatic disease. A recent proof-of-principle 377 
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study using rapid microbiota-based diagnosis (<12 hours) for severe pneumonia in adults, underlines 378 
that such diagnostic tools improve diagnostic accuracy and could be within reach.29 If the cost such 379 
technology reduces further and becomes available for pediatric use, we might be able to refrain from 380 
broad-spectrum antibiotics more often, and could instead specifically target the most abundant or 381 
overgrowing species by small-spectrum agents.30 Although our microbiota-based approach has to be 382 
validated in independent cohorts, the non-inferior performance of the genus-level model suggests 383 
potential for future development of universal or country/region-based models, also in the context of 384 
prediction of severity and duration of disease by combined microbiota and host characteristics. This 385 
would potentially allow the physician to increase or decrease the threshold for antimicrobial treatment 386 
depending on the predicted outcome. 387 
A second implication of our findings results from the observation that specific consortia of 388 
microorganisms are associated with health. Given these data are in line with multiple recent studies 389 
across the globe,6,8,31–33 our findings urge for new studies to obtain mechanistic insight into their potential 390 
role in prevention of respiratory disease. For Corynebacterium spp. it was already reported to reduce 391 
virulence of S. aureus and inhibit S. pneumoniae growth in vitro.34,35 Moreover, nasal application of 392 
Corynebacterium spp. induced resistance against RSV and secondary pneumococcal pneumonia in 393 
infant mice.36 Together, all studies prompt for future research efforts to assess the (combined) effects of 394 
these commensal bacteria in modulation of the respiratory ecosystem, especially the containment of 395 
potential pathogens such as RSV, Haemophilus and Streptococcus spp. and host immune responses 396 
underlying respiratory symptoms. 397 
A third potential implication follows from the observed phenotype-independent relation of viral and 398 
bacterial microbiota with LRTIs. This parallels the highly overlapping clinical presentations of these 399 
phenotypes in children, resulting in the lack of a robust gold standard for accurate classification and 400 
treatment.37 Our findings contribute to the paradigm shift that is currently arising, demonstrating that 401 
viruses contribute to presumed bacterial pneumonia38 and vice versa that bacteria seem to have an 402 
important role in pathogenesis and severity of presumed viral bronchiolitis9 and wheezing illness,39 403 
suggesting the inappropriateness of these conventional single bacteria- and virus-centric views 404 
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following Koch’s postulates. Our findings also allude to the hypothesis that there is a universal pathway 405 
for the development of clinical LRTIs, linked to microbial dysbiosis, where clinical phenotypes are 406 
driven more by host (e.g. age, anatomy, baseline mucosal inflammation, status of innate and adaptive 407 
immunity, and genetic background) and environment rather than by single pathogen characteristics. This 408 
also underlines that treatment decisions for the time being should not be made on clinical phenotype, 409 
but rather on severity of disease. We fully realize we are only at the start of this scientific debate, and 410 
many discussions among and between clinicians, microbiologists, and biologists need to take place, as 411 
well as confirmatory studies of our results. However, technically and practically tools are there to adapt 412 
diagnostic and treatment protocols within the coming 5 years if the community finds this suitable. 413 
The major strength of our study is the strictly matched case-control design, which precludes bias from 414 
the confounding effects of age, time, and gender. Moreover, the unselected recruitment of cases provides 415 
conclusive evidence in a cohort that highly represents the patients seen by pediatric clinicians. Last, the 416 
consistent patterns in our unsupervised and supervised analyses contribute to the robustness of our 417 
results.  418 
Our study also has limitations. First, case-control designs could theoretically introduce selection bias. 419 
Second, only known respiratory viruses were detected by qPCR-based assays, but not the entire 420 
respiratory virome. However, virome studies report a high concordance between the results of 421 
metagenomic sequencing and qPCR-based assays.40 Third, as with any observational study, our findings 422 
do not necessarily prove causality. Longitudinal analyses are underway to address cause-consequence 423 
analyses. Fourth, the endotracheal aspirate may not provide a perfect reflection of the lower respiratory 424 
tract microbiota extending into the bronchi and alveoli. That said, clinical evidence based on 425 
conventional  microbiology data up till now have suggested that tracheal aspirates are a good proxy for 426 
the lower respiratory tract, and therefore an appropriate proxy for the clinical diagnosis of cause of 427 
disease in children with severe LRTI.41 Furthermore, recent evidence showed a strong concordance with 428 
negligible differences between bacterial microbiota from endotracheal samples and bronchial lavages.42 429 
Finally, fifth, it should be underlined that 16S rRNA sequencing only permits annotation up to in 430 
between genus- and species-level identification of bacteria, and does not provide the resolution of 431 
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metagenomic techniques such as shotgun sequencing, especially regarding closely related species such 432 
as streptococcal species. We tried to provide also some more species-level data by qPCR for 433 
confirmation of the four common and potentially pathogen OTUs, supporting our conclusions. Future 434 
studies might therefore be needed on multiple levels to further confirm our data, and refine the 435 
conclusions. 436 
In conclusion, our findings urge for further exploration of microbiota-based diagnostics, as well as for 437 
further validation of our prediction model for severity of disease in different settings and countries, to 438 
explore their usefulness in optimizing treatment, and improve antimicrobial stewardship.  439 
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Table and Figures 572 
Table 1. Baseline characteristics for the cases and their matched controls. 573 
Data on medication use was acquired by pharmacy printouts, whereas the rest of the data was acquired 574 
by parent questionnaires. Breastfeeding was nonexclusive. Educational level was classified into three 575 
categories: low level (primary school education or pre-vocational education as highest qualification), 576 
intermediate (selective secondary education or vocational education) and high level (university of 577 
applied sciences and research university). Smoke exposure included children who were exposed to 578 
second-hand tobacco smoke. P values were determined by univariate conditional logistic regression. 579 
Matching factors were not tested. IQR = interquartile range; RTI = respiratory tract infection; LRTI = 580 
any parental-reported lower RTI. 581 
 
Cases Controls P value 
n 154 307 
 
Basics    
   Girl (%) 61 (39·6) 122 (39·7) 
 
   Age (months) (median [IQR]) 13·6 [4·9, 27·4] 14·1 [5·3, 28·4] 
 
   Born at term (%) 142 (92·2) 294 (95·8) 0·111 
   Mode of delivery (%) 
  
0·457 
      vaginal 124 (80·5) 260 (84·7) 
 
      elective C-section 15 (9·7) 26 (8·5) 
 
      emergency C-section 15 (9·7) 21 (6·8) 
 
   Season of sampling (%) 
   
      Spring 49 (32·0) 91 (29·6) 
 
      Summer 22 (14·4) 44 (14·3) 
 
      Autumn 8 (5·2) 19 (6·2) 
 
      Winter 74 (48·4) 153 (49·8) 
 
Medical History 
   
   LRTI (%) 38 (25·0) 22 (7·2) <0·001 
   Wheezing (%) 41 (26·6) 22 (7·2) <0·001 
   Otitis (%) 38 (24·7) 46 (15·0) 0·008 
   Hospitalization for RTI (%) 33 (21·7) 10 (3·3) <0·001 
Medication 
   
   Antibiotics past 6 months (%) 41 (27·2) 19 (6·2) <0·001 
Feeding 
   
   Breastfeeding >3 months (%) 58 (37·7) 169 (55·0) <0·001 
Family 
   
   Education level parents (%) 
  
<0·001 
      high 99 (64·7) 262 (85·3) 
 
      intermediate 49 (32·0) 42 (13·7) 
 
      low 5 (3·3) 3 (1·0) 
 
   Siblings (median [IQR]) 1·0 [1·0, 2·0] 1·0 [0·0, 1·0] 0·002 
Environment 
   
   Smoke exposure (%) 36 (23·4) 44 (14·3) 0·015 
  582 
Page 25 of 32 
 
 25 
Figure 1. Viral PCR positivity in cases and controls. 583 
The proportions of qPCR respiratory virus detections for cases (red, n=148) and controls (green, n=302). 584 
 585 
586 
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Figure 2. NMDS biplot. 587 
NMDS biplot depicting the individual nasopharyngeal microbiota composition (data points, n=457) 588 
colored by subcohort: LRTI-cases at admission (red, n=151) and matched controls (green, n=306). 589 
Ellipses represent the standard deviation of all points within a cohort. In addition, figure A depicts the 590 
9 bacterial species biomarkers (determined by Random Forest analysis on hierarchical clustering 591 
results). Figure B adds a posteriori projection of covariates that significantly explained the compositional 592 
variation between cases and controls (grey = significant in univariable analysis, black = significant in 593 
multivariable analysis). For readability, only a selection of the covariates explaining the largest variation 594 
are displayed. In addition, the association with age (purple) has been included to demonstrate that the 595 
age-effect (vertical orientation for younger vs. older subjects) was perpendicular (~90° angle) to the 596 
disease-health axis (horizontal orientation), showing that age-related differences in microbiota 597 
composition per se are not associated with disease. Stress: 0·269. 598 
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Figure 3. Random forest models classifying disease and health based on 16S rRNA data, viral 601 
presence and patient characteristics combined. 602 
Twenty-four variables were discriminating cases from controls in the unstratified cohort (n=457; B) 603 
leading to a sparse classification model with an AUC of 0·92 (A). Variables are ranked in descending 604 
order based on their importance to the accuracy of the model. Variable importance was estimated by 605 
calculating the mean decrease in Gini after randomly permuting the values of each given variable (mean 606 
± standard deviation, 100 replicates). The direction of the associations was estimated post-hoc using 607 
point biserial correlations (green = associated with health; red = associated with disease). The disease-608 
discriminatory variables for the pneumonia cases (brown, n=108; C), bronchiolitis cases (purple, n=171; 609 
D), wheezing illness cases (dark green, n=100; E), and mixed-phenotype cases (pink, n=78; F) versus 610 
their matched controls are depicted in figures C-F (light colored bars are positively associated with 611 
health). The ROC curves for distinguishing disease from health of these stratified sparse random forest 612 
classifying models are depicted in A. 613 
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